Cordis and Medinol announced today that the first commercial uses of the Elunir drug-eluting stent in the U.S. were performed at New York-Presbyterian Hospital/Columbia University Medical Center and the Piedmont Heart Institute in Atlanta.
The Elunir stent, developed by Medinol and distributed by Cordis, features a metallic spring tip and the narrowest strut width of any stent on the U.S. market, according to the two companies. The device is designed to treat patients with narrowed or blocked coronary arteries.
Get the full story at our sister site, Drug Delivery Business News.
The post Cordis, Medinol tout first commercial implants of Elunir drug-eluting stent in U.S. appeared first on MassDevice.